Figure 1.
Study schema. APL, acute promyelocytic leukemia; BD, twice daily; IDA, idarubicin; IDAC, intermediate-dose cytarabine.

Study schema. APL, acute promyelocytic leukemia; BD, twice daily; IDA, idarubicin; IDAC, intermediate-dose cytarabine.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal